drugset / Trial / NCT01965145
Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study is to demonstrate the superiority of gevokizumab as compared to placebo on top of current standard of care in reducing the risk of Behçet's disease uveitis exacerbations
Timeline
- Start
- 2012-11
- Primary completion
- 2015-07
- Completion
- 2015-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gevokizumab | Monoclonal antibody | 60 mg | Subcutaneous |